Home / Obesity (page 6)

Obesity

GLP‑1s for the Long Haul: Having Honest Conversations About Safety and Side Effects

Visual representation of GLP‑1 long‑term safety including digestive anatomy, pancreatitis risk, patient symptoms, medication, and nutrition.

GLP‑1 receptor agonists have changed the way we treat type 2 diabetes and obesity, offering powerful glucose-lowering effects and sustained weight loss. But as more patients stay on these medications for years—not just months—questions around GLP‑1 long‑term safety have become essential to address. From gastrointestinal discomfort to gallbladder risks and …

Read More »

Inside the GLP‑1 Mechanism: How One Pathway Reaches Heart, Liver, Brain, and Beyond

Medical illustration showing the GLP-1 mechanism of action impacting the brain, heart, liver, and pancreas with insulin and glucagon pathways.

The GLP‑1 mechanism of action is more than a tool for lowering glucose—it’s a central player in a complex system influencing body weight, cardiovascular outcomes, liver health, and possibly even brain function. As GLP‑1 receptor agonists become more widely prescribed, understanding how this pathway works helps clinicians better tailor treatments …

Read More »

When to Refer for Metabolic Surgery in Type 2 Diabetes and What to Expect

Doctor discussing metabolic surgery options with a patient for type 2 diabetes, with gastric bypass model and diabetes tools on desk.

Could metabolic surgery be the turning point for your patients with type 2 diabetes who aren’t seeing results with medication alone? As evidence mounts around the success of metabolic surgery type 2 diabetes treatment, more clinicians are exploring when and how to refer patients. This guide explains who qualifies, what …

Read More »

Bridging the GLP‑1 Access Gap: Equity Strategies in a High‑Demand Era

Diverse healthcare team discussing GLP‑1 therapy access with medical tools and cost symbols in the foreground, illustrating treatment equity challenges.

As GLP‑1 drugs become more widely used for managing type 2 diabetes and obesity, concerns about access disparities have intensified. Unequal distribution and affordability threaten to create a two-tier healthcare system—where only those with greater means receive these life-changing therapies. In this article, we explore the concept of GLP‑1 access …

Read More »

GLP‑1 Therapies for Obesity: How the WHO’s New Stance Impacts Diabetes Care

GLP-1 therapy injection pen on a diabetes and obesity medical report surrounded by healthy foods and a stethoscope.

Obesity is no longer just a lifestyle issue — it’s now globally recognized as a chronic, relapsing disease. In a bold move, the World Health Organization (WHO) has formally endorsed GLP‑1 therapy obesity treatments for long-term management in adults. This policy shift holds significant implications for diabetes care, especially as …

Read More »

Why Screening for Sleep Apnea Should Be Standard in Diabetes Care

A CPAP nasal mask and tubing placed beside diabetes and sleep apnea screening questionnaires, including the STOP-Bang tool.

In clinical practice, the link between sleep apnea diabetes screening and improved patient outcomes is becoming increasingly clear. Obstructive sleep apnea (OSA) is both a contributor to and a consequence of poor glycemic control, yet it remains under‑recognized in diabetes management. If clinicians fail to screen for sleep apnea in …

Read More »